Roberto Sabbatini
Impact in
- Reproductive Medicine top 0.5%
- Ovarian cancer diagnosis and treatment
- Oncology top 0.5%
- PARP inhibition in cancer therapy
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Renal cell carcinoma treatment 46
- Prostate Cancer Treatment and Research 12
- Oncology 40
- Cancer Immunotherapy and Biomarkers 12
- Co-authors
- Camillo Porta (21 shared papers)Silvia Fabiani (8 shared papers)Paolo Del Giovane (5 shared papers)Giuseppe Procopio (14 shared papers)Roberta Depenni (5 shared papers)Cinzia Ortega (9 shared papers)Fernando Martins (6 shared papers)Massimo Dominici (17 shared papers)
- Journals
- Annals of Oncology (13 papers)European Journal of Cancer (8 papers)Expert Review of Anticancer Therapy (5 papers)Journal of Clinical Oncology (4 papers)Future Oncology (4 papers)
- Partner nations
- ItalyUnited StatesCanada
In The Last Decade
Roberto Sabbatini
131 papers receiving 6.5k citations
Roberto Sabbatini's Hit Papers
Peers
Comparison fields: 5 of 115
- Reproductive Medicine 1.3k
- Oncology 3.6k
- Pulmonary and Respiratory Medicine 1.8k
- Cancer Research 744
- Obstetrics and Gynecology 188
Countries citing papers authored by Roberto Sabbatini
This map shows the geographic impact of Roberto Sabbatini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roberto Sabbatini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roberto Sabbatini more than expected).
Fields of papers citing papers by Roberto Sabbatini
This network shows the impact of papers produced by Roberto Sabbatini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roberto Sabbatini. The network helps show where Roberto Sabbatini may publish in the future.
Co-authors
The 25 scholars most cited alongside Roberto Sabbatini, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 136 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial Hit paper breakdown → | 2017 | 1562 |
| 2 | Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2017 | 1394 |
| 3 | Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma Hit paper breakdown → | 2014 | 356 |
| 4 | Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial Hit paper breakdown → | 2021 | 319 |
| 5 | Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2022 | 210 |
| 6 | 2019 | 157 | |
| 7 | 2019 | 125 | |
| 8 | 2010 | 110 | |
| 9 | Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study Hit paper breakdown → | 2024 | 97 |
| 10 | 2017 | 93 | |
| 11 | 2015 | 89 | |
| 12 | 2003 | 81 | |
| 13 | 2011 | 78 | |
| 14 | 2018 | 76 | |
| 15 | 2019 | 76 | |
| 16 | 2013 | 72 | |
| 17 | 2014 | 71 | |
| 18 | 2015 | 71 | |
| 19 | 2014 | 66 | |
| 20 | 2012 | 60 |
About Roberto Sabbatini
Roberto Sabbatini is a scholar working on Pulmonary and Respiratory Medicine, Oncology, General Economics, Econometrics and Finance, Economics and Econometrics and Cancer Research, having authored 136 papers that have together received 6.6k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (46 papers), Italy: Economic History and Contemporary Issues (14 papers), Cancer Immunotherapy and Biomarkers (12 papers), Monetary Policy and Economic Impact (12 papers), Prostate Cancer Treatment and Research (12 papers), Cancer Genomics and Diagnostics (10 papers), Bladder and Urothelial Cancer Treatments (10 papers) and Renal and related cancers (9 papers). The work is most often cited by research in Reproductive Medicine (1.3k citations), Oncology (3.6k citations), Pulmonary and Respiratory Medicine (1.8k citations), Cancer Research (744 citations) and Obstetrics and Gynecology (188 citations). Roberto Sabbatini has collaborated with scholars based in Italy, United States and Canada. Frequent co-authors include Camillo Porta, Silvia Fabiani, Paolo Del Giovane, Giuseppe Procopio, Roberta Depenni, Cinzia Ortega, Fernando Martins, Massimo Dominici, Maria Giuseppa Vitale and Chiara Paglino. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, Expert Review of Anticancer Therapy, Journal of Clinical Oncology and Future Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.